Preferred Label : Maraviroc;
MeSH definition : A cyclohexane and triazole derivative that acts as an antagonist of the CCR5 RECEPTOR.
It prevents infection by HIV-1 virus strains which use CCR5 as a co-receptor for membrane
fusion and cellular entry.;
MeSH synonym : 4,4-Difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide;
MeSH hyponym : UK 427,857; UK427,857; UK-427857; UK 427857; UK427857;
MeSH CAS label : Cyclohexanecarboxamide, 4,4-difluoro-N-((1S)-3-((3-exo)-3-(3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)-;
UNII : MD6P741W8A;
Origin ID : D000077592;
UMLS CUI : C1667052;
ATC code(s)
Allowable qualifiers
MeSH indexing information
Pharmacological action(s)
Record concept(s)
Semantic type(s)
Validated automatic mappings to BTNT
A cyclohexane and triazole derivative that acts as an antagonist of the CCR5 RECEPTOR.
It prevents infection by HIV-1 virus strains which use CCR5 as a co-receptor for membrane
fusion and cellular entry.
https://www.has-sante.fr/portail/jcms/c_2869665/fr/celsentri
2018
false
true
false
false
France
French
evaluation of the transparency committee
adolescent
child
adult
treatment outcome
HIV-1
hiv infections
hiv infections
CCR5 Receptor Antagonists
CCR5 Receptor Antagonists
Genotype drug resistance test
maraviroc
administration, oral
drug therapy, combination
selzentry
cyclohexanes
triazoles
cyclohexanes
triazoles
cyclohexanes
triazoles
Maraviroc
Maraviroc
Maraviroc
---
https://www.has-sante.fr/portail/jcms/c_2848372/fr/celsentri
https://www.has-sante.fr/portail/jcms/c_2848372/fr/celsentri-maraviroc-antiretroviral-antagoniste-du-recepteur-ccr5
2018
false
false
false
false
France
French
evaluation of the transparency committee
adolescent
child
adult
treatment outcome
guidelines for drug use
HIV-1
hiv infections
hiv infections
CCR5 Receptor Antagonists
CCR5 Receptor Antagonists
Genotype drug resistance test
maraviroc
selzentry
cyclohexanes
triazoles
cyclohexanes
triazoles
cyclohexanes
triazoles
Maraviroc
Maraviroc
---
https://pharmacomedicale.org/medicaments/par-specialites/item/autres-antiretroviraux
2016
false
false
false
France
French
drug information
hiv fusion inhibitors
hiv infections
enfuvirtide
maraviroc
CCR5 Receptor Antagonists
Raltegravir Potassium
raltegravir
HIV integrase inhibitors
anti-retroviral agents
peptide fragments
HIV envelope protein gp41
cyclohexanes
triazoles
Enfuvirtide
Maraviroc
---
http://www.has-sante.fr/portail/jcms/c_2561558/fr/celsentri
2015
false
false
false
France
French
evaluation of the transparency committee
cyclohexanes
triazoles
Maraviroc
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=61182724
2012
France
summary of product characteristics
package leaflet
tablets
Maraviroc
---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=62094362
2012
France
summary of product characteristics
package leaflet
tablets
Maraviroc
---
https://www.ema.europa.eu/medicines/human/EPAR/Celsentri
2012
false
United Kingdom
English
French
CCR5 Receptor Antagonists
CCR5 Receptor Antagonists
syndication feed
hiv infections
hiv fusion inhibitors
cyclohexanes
tablets
administration, oral
adult
HIV-1
acquired immunodeficiency syndrome
drug therapy, combination
cyclohexanes
cyclohexanes
triazoles
triazoles
hiv fusion inhibitors
hiv fusion inhibitors
treatment outcome
cyclohexanes
triazoles
hiv fusion inhibitors
drug interactions
drug approval
drug labeling
pregnancy
triazoles
triazoles
cyclohexanes
hiv fusion inhibitors
drug resistance, viral
triazoles
cyclohexanes
hiv fusion inhibitors
drug evaluation, preclinical
breast feeding
maraviroc
summary of product characteristics
drug evaluation
package leaflet
Maraviroc
Maraviroc
---
http://www.has-sante.fr/portail/jcms/c_865545/tests-de-determination-du-tropisme-du-vih-1-dans-le-cadre-du-traitement-avec-un-antagoniste-du-recepteur-a-chimiokines-ccr5
http://www.has-sante.fr/portail/jcms/c_870286/rapport-tests-de-tropisme
2009
true
France
French
CCR5 Receptor Antagonists
HIV-1
viral tropism
cyclohexanes
triazoles
hiv infections
anti-retroviral agents
hiv fusion inhibitors
phenotype
genotype
health technology assessment
treatment outcome
Maraviroc
---
http://www.has-sante.fr/portail/jcms/c_676960/celsentri
2008
France
evaluation of the transparency committee
Maraviroc
---
https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Celsentri_Final_Nov-12-08-fr.pdf
2008
false
Canada
French
CCR5 Receptor Antagonists
triazoles
hiv fusion inhibitors
cyclohexanes
insurance, health, reimbursement
HIV-1
drug therapy, combination
hiv infections
adult
tablets
administration, oral
drug costs
treatment outcome
canada
maraviroc
drug evaluation
Maraviroc
---
https://www.cadth.ca/sites/default/files/pdf/E0036_Maraviroc_cetap_fr.pdf
https://www.cadth.ca/sites/default/files/pdf/E0036_Maraviroc_cetap_e.pdf
2007
false
Canada
French
English
CCR5 Receptor Antagonists
CCR5 Receptor Antagonists
CCR5 Receptor Antagonists
triazoles
hiv infections
HIV-1
hiv fusion inhibitors
cyclohexanes
drug resistance, multiple, viral
treatment outcome
adult
Evidence-Based medicine
cyclohexanes
cyclohexanes
triazoles
triazoles
hiv fusion inhibitors
hiv fusion inhibitors
canada
randomized controlled trials as topic
maraviroc
drug evaluation
Maraviroc
Maraviroc
Maraviroc
---